

## NP/PA Prescribing Regulations

The enactment and effective date of CARA for NPs and PAs began July 22<sup>nd</sup>, 2016 and ends October 1<sup>st</sup>, 2021. This extends buprenorphine prescribing to NPs and PAs to begin taking required training in order to apply for waivers starting in 2017. CARA doesn't require that the supervisor or collaborative physician of an NP or PA be a waived physician, but the qualifying physician *must meet one of the conditions attached as defined by CARA. Please contact us below for further information or questions. Citation: Civic Impulse (2017). S. 524 – 114<sup>th</sup> Congress: Comprehensive Addiction and Recovery Act of 2016. <https://www.govtrack.us/congress/bills/114/s524>*

## Upcoming Training Opportunities in NYS & NYC

You can attend these *free buprenorphine waiver trainings* in-person as half-day trainings to fulfill the initial 4-hour training requirement of the total 24 hours of training required for NPs & PAs:

Free <u>NYS</u> Buprenorphine Waiver Trainings	
Thursday, October 12 <sup>th</sup> , 2017, 1:00-5:30PM	New York State Society of Physician Assistants Conference (Tarrytown, NY), <a href="#">DoubleTree by Hilton Tarrytown</a>
<p><b>Register HERE!</b> <i>Free Buprenorphine Waiver Training (open to all) at the <a href="#">NYS Society of Physician Assistants Conference</a></i></p> <p><b>NOTE:</b> <i>While attendance and registration for this training is free, you <u>must</u> register for the waiver training on the NYSSPA conference website <a href="#">here</a>. You must register and pay for any other portions of the conference that you wish to attend.</i></p>	
Thursday, October 19 <sup>th</sup> , 2017, 12:30-5:30PM	The Nurse Practitioners Association (NPA) New York State 33 <sup>rd</sup> Annual Conference (Saratoga Springs, NY), <a href="#">Saratoga Springs City Center</a>
<p><b>Register HERE!</b> <i>Free Buprenorphine Waiver Training for Nurse Practitioners &amp; Clinical Providers (Physicians, Physician Assistants, Pharmacists, and Medical Residents are welcome) at the <a href="#">33<sup>rd</sup> Annual NPA Conference</a>, CME credits available, flyer attached with further information.</i></p> <p><b>NOTE:</b> <i>While attendance and registration for this training is free, you <u>must</u> register for the waiver training at the NPA conference <a href="#">here</a>. You must register and pay for any other portions of the conference that you wish to attend.</i></p>	
Free <u>NYCDOHMH</u> Buprenorphine Waiver Trainings	
Wednesday, September 27 <sup>th</sup> , 2017, 12:00-5:00PM	Manhattan, NYC Health + Hospitals/Metropolitan
<p><i>To register, send name, email, title, affiliation, and practice address to <a href="mailto:buprenorphine@health.nyc.gov">buprenorphine@health.nyc.gov</a>. CME credits available. Attendance is limited to providers living or working in NYC.</i></p>	
Thursday, September 28 <sup>th</sup> , 2017, 1:00-5:30PM	Bronx, Montefiore Medical Center
<p><i>To register, send name, email, title, affiliation, and practice address to <a href="mailto:buprenorphine@health.nyc.gov">buprenorphine@health.nyc.gov</a>. CME credits available. Attendance is limited to providers living or working in NYC.</i></p>	

Friday, October 27<sup>th</sup>, 2017, 1:00-5:30PM

Bronx, Montefiore Medical Center

To register, send name, email, title, affiliation, and practice address to [buprenorphine@health.nyc.gov](mailto:buprenorphine@health.nyc.gov). CME credits available. Attendance is limited to providers living or working in NYC.

Additionally, [Providers' Clinical Support System for Medication Assisted Treatment \(PCSS-MAT\)](#) launched its free 24-hour course specifically developed for NPs and PAs to treat opioid use disorder (OUD). The required [24 hours of coursework](#) is broken up into an 8-hour MAT waiver training and 16 hours of training for treating OUD.

## Contact Us

- The NYSDOH and NYCDOHMH both offer free buprenorphine waiver trainings, mentoring, coaching, technical assistance, resources and more.
  - To learn more about these services throughout NYS (outside of NYC) email [buprenorphine@health.ny.gov](mailto:buprenorphine@health.ny.gov) or call 1-800-692-8528.
  - To learn more about these services throughout NYC (the 5 boroughs only) email [buprenorphine@health.nyc.gov](mailto:buprenorphine@health.nyc.gov).
- For further information about the NYSDOH, AIDS Institute's, Office of Drug User Health, visit: <http://www.health.ny.gov/diseases/aids/consumers/prevention/>

## Qualifying physician Requirements for PAs and NPs supervision/collaboration

130 STAT. 722

PUBLIC LAW 114-198—JULY 22, 2016

the nurse practitioner or physician assistant to treat and manage opiate-dependent patients.

“(III) The nurse practitioner or physician assistant is supervised by, or works in collaboration with, a qualifying physician, if the nurse practitioner or physician assistant is required by State law to prescribe medications for the treatment of opioid use disorder in collaboration with or under the supervision of a physician.

The Secretary may, by regulation, revise the requirements for being a qualifying other practitioner under this clause.”; and

(D) in subparagraph (H)—

(i) in clause (i), by inserting after subclause (II) the following:

### Title 21 United States Code (USC) Controlled Substances Act as amended by the Comprehensive Addiction and Recovery Act of 2016

#### 21USC823(g)(2)(G)(ii)

**(g) Practitioners dispensing narcotic drugs for narcotic treatment; annual registration; separate registration; qualifications; waiver**

.....

(i) The practitioner is a **qualifying** physician (as defined in subparagraph (G)).

.....

(G) For purposes of this paragraph:

(ii) The term "**qualifying physician**" means a physician who is licensed under State law and who meets one or more of the following conditions:

(I) The physician **holds a subspecialty board certification in addiction psychiatry** from the American Board of Medical Specialties.

(II) The physician **holds an addiction certification** from the American Society of Addiction Medicine.

(III) The physician **holds a subspecialty board certification in addiction medicine** from the American Osteopathic Association.

(IV) The physician has, with respect to the treatment and management of opiate-dependent patients, **completed not less than eight hours of training** (through classroom situations, seminars at professional society meetings, electronic communications, or otherwise) that is provided by the American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the American Medical Association, the American Osteopathic Association, the American Psychiatric Association, or any other organization that the Secretary determines is appropriate for purposes of this subclause.

(V) The physician **has participated as an investigator** in one or more clinical trials leading to the approval of a narcotic drug in schedule III, IV, or V for maintenance or detoxification treatment, as demonstrated by a statement submitted to the Secretary by the sponsor of such approved drug.

(VI) The physician **has such other training or experience as the State medical licensing board** (of the State in which the physician will provide maintenance or detoxification treatment) considers to demonstrate the ability of the physician to treat and manage opiate-dependent patients.

(VII) The physician **has such other training or experience as the Secretary** considers to demonstrate the ability of the physician to treat and manage opiate-dependent patients. Any criteria of the Secretary under this subclause shall be established by regulation. Any such criteria are effective only for 3 years after the date on which the criteria are promulgated, but may be extended for such additional discrete 3-year periods as the Secretary considers appropriate for purposes of this subclause. Such an extension of criteria may only be effectuated through a statement published in the Federal Register by the Secretary during the 30-day period preceding the end of the 3-year period involved.

(H)(i) In consultation with the Administrator of the Drug Enforcement Administration, the Administrator of the Substance Abuse and Mental Health Services Administration, the Director of the National Institute on Drug Abuse, and the Commissioner of Food and Drugs, the Secretary shall issue regulations (through notice and comment rulemaking) or issue practice guidelines to address the following:

(I) Approval of additional credentialing bodies and the responsibilities of additional credentialing bodies.

(II) Additional exemptions from the requirements of this paragraph and any regulations under this paragraph.

Nothing in such regulations or practice guidelines may authorize any Federal official or employee to exercise supervision or control over the practice of medicine or the manner in which medical services are provided.

(ii) Not later than 120 days after October 17, 2000, the Secretary shall issue a treatment improvement protocol containing best practice guidelines for the treatment and maintenance of opiate-dependent patients. The Secretary shall develop the protocol in consultation with the Director of the National Institute on Drug Abuse, the Administrator of the Drug Enforcement Administration, the Commissioner of Food and Drugs, the Administrator of the Substance Abuse and Mental Health Services Administration and other substance abuse disorder professionals. The protocol shall be guided by science.

(I) During the 3-year period beginning on the date of approval by the Food and Drug Administration of a drug in schedule III, IV, or V, a State may not preclude a practitioner from dispensing or prescribing such drug, or combination of such drugs, to patients for maintenance or detoxification treatment in accordance with this paragraph unless, before the expiration of that 3-year period, the State enacts a law prohibiting a practitioner from dispensing such drugs or combinations of drug.\1\

# FREE Buprenorphine Waiver



Department  
of Health

AIDS  
Institute

## Training for NPs & Clinical Providers

# Thursday, October 19<sup>th</sup>, 2017

## 12:30 – 5:30PM | Saratoga Springs

### The Nurse Practitioner Association New York State (The NPA) 33<sup>rd</sup> Annual Conference

The NYSDOH, AIDS Institute is sponsoring a [Free Buprenorphine Waiver Training for Nurse Practitioners \(NPs\)](#). In response to the opioid overdose deaths in New York State, increased access to buprenorphine treatment for opioid overdose disorder is urgently needed, and NPs are paving the way to ensure patients obtain access to this highly effective treatment. Since the Comprehensive Addiction and Recovery Act (CARA) was passed in 2016, the number of NPs obtaining their waivers has drastically increased. [Physicians, Physician Assistants, Pharmacists and Medical Residents](#) are also welcome and highly encouraged to attend this training.

Under current regulations, authorized practitioners (MDs, DOs, NPs & PAs) are required to obtain a 'waiver' to prescribe buprenorphine. To acquire this waiver, physicians are required to complete a standardized buprenorphine waiver 8-hour training. Nurse Practitioners (NPs) and Physician Assistants (PAs) are required to complete the standardized buprenorphine waiver 8-hour training as well as an additional 16 hours of online training as established by CARA. The buprenorphine waiver 8-hour training is offered in a half-and-half format [3.5 hours of online training completed after 4.5 hours of the live training]. Upon completion of the required training, providers will meet the requirement of the DATA 2000 to apply for a waiver to prescribe buprenorphine for opioid-dependent patients. *Please contact us for further information.*

**CME CREDITS:** The School of Public Health, University at Albany is accredited by the Medical Society of the State of New York (MSSNY) to provide continuing medical education for physicians. The School of Public Health, University at Albany designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Trainers:** Samara Gabree, NP, Catholic Charities, Albany, NY; Bruce Trigg, MD, Harm Reduction Coalition, New York, NY; Melissa Weimer, DO, MCR, St. Peter's Health Partners

**Where:** Saratoga Springs City Center, 522 Broadway, Meeting Room 1, Saratoga Springs, NY 12866

**Directions:** <https://goo.gl/maps/fSvUTW5MYUv>

**Online Registration:** <http://events.eventzilla.net/e/buprenorphine-waiver-training-2138929197>

**Questions:** NYSDOH, AIDS Institute, Office of Drug User Health

Lyla Hunt, 518-473-7428, [buprenorphine@health.ny.gov](mailto:buprenorphine@health.ny.gov)

**ACCREDITATION:** This activity has been planned and implemented by NYSDOH, AIDS Institute in accordance with the accreditation requirements and policies of the American Academy of Addiction Psychiatry (AAAP) and in partnership with The Nurse Practitioner Association New York State (The NPA) and Harm Reduction Coalition.

Funding for this course was made possible (in part) by 1U79T1026556 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. American Academy of Addiction Psychiatry is the sponsoring data organization.

